Molecular Oncology
Volume 1, Issue 3 , Pages 269-287 , December 2007

New insights into the functional mechanisms and clinical applications of the kallikrein-related peptidase family

  • Nashmil Emami

      Affiliations

    • Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario M5G 1L5, Canada
    • Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario M5G 1X5, Canada
    • ,
  • Eleftherios P. Diamandis

      Affiliations

    • Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario M5G 1L5, Canada
    • Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario M5G 1X5, Canada
    • Corresponding Author InformationCorresponding author. Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario M5G 1X5, Canada. Tel.: +1 416 586 8443; fax: +1 416 619 5521.

Received 13 July 2007 ,Revised 4 September 2007 ,Accepted 7 September 2007.

References 

  1. Amour A, Bird M, Chaudry L, Deadman J, Hayes D, Kay C. General considerations for proteolytic cascades. Biochem. Soc. Trans. 2004;32:15–16
  2. Angelo PF, Lima AR, Alves FM, Blaber SI, Scarisbrick IA, Blaber M, et al. Substrate specificity of human kallikrein 6: salt and glycosaminoglycan activation effects. J. Biol. Chem. 2006;281:3116–3126
  3. Bakin RE, Gioeli D, Sikes RA, Bissonette EA, Weber MJ. Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res. 2003;63:1981–1989
  4. Bando Y, Ito S, Nagai Y, Terayama R, Kishibe M, Jiang YP, et al. Implications of protease M/neurosin in myelination during experimental demyelination and remyelination. Neurosci. Lett. 2006;405:175–180
  5. Barrett AJ, Rawlings ND, Woessner JF. Handbook of Proteolytic Enzymes. San Diego: Academic Press Inc; 2004;
  6. Bayes A, Tsetsenis T, Ventura S, Vendrell J, Aviles FX, Sotiropoulou G. Human kallikrein 6 activity is regulated via an autoproteolytic mechanism of activation/inactivation. Biol. Chem. 2004;385:517–524
  7. Beato M. Gene regulation by steroid hormones. Cell. 1989;56:335–344
  8. Beaufort N, Debela M, Creutzburg S, Kellermann J, Bode W, Schmitt M, et al. Interplay of human tissue kallikrein 4 (hK4) with the plasminogen activation system: hK4 regulates the structure and functions of the urokinase-type plasminogen activator receptor (uPAR). Biol. Chem. 2006;387:217–222
  9. Bernett MJ, Blaber SI, Scarisbrick IA, Dhanarajan P, Thompson SM, Blaber M. Crystal structure and biochemical characterization of human kallikrein 6 reveals that a trypsin-like kallikrein is expressed in the central nervous system. J. Biol. Chem. 2002;277:24562–24570
  10. Bindukumar B, Schwartz SA, Nair MP, Aalinkeel R, Kawinski E, Chadha KC. Prostate-specific antigen modulates the expression of genes involved in prostate tumor growth. Neoplasia. 2005;7:241–252
  11. Biyashev D, Tan F, Chen Z, Zhang K, Deddish PA, Erdos EG, et al. Kallikrein activates bradykinin B2 receptors in absence of kininogen. Am. J. Physiol Heart Circ. Physiol. 2006;290:H1244–H1250
  12. Borg TK. It's the matrix! ECM, proteases, and cancer. Am. J. Pathol. 2004;164:1141–1142
  13. Borgono CA, Diamandis EP. The emerging roles of human tissue kallikreins in cancer. Nat. Rev. Cancer. 2004;4:876–890
  14. Borgono CA, Grass L, Soosaipillai A, Yousef GM, Petraki CD, Howarth DH, et al. Human kallikrein 14: a new potential biomarker for ovarian and breast cancer. Cancer Res. 2003;63:9032–9041
  15. Borgono CA, Michael IP, Diamandis EP. Human tissue kallikreins: physiologic roles and applications in cancer. Mol. Cancer Res. 2004;2:257–280
  16. Borgono CA, Michael IP, Komatsu N, Jayakumar A, Kapadia R, Clayman GL, et al. A potential role for multiple tissue kallikrein serine proteases in epidermal desquamation. J. Biol. Chem. 2006;282:3640–3652
  17. Borgono CA, Michael IP, Shaw JL, Luo LY, Ghosh MC, Soosaipillai A, et al. Expression and functional characterization of the cancer-related serine protease, human tissue kallikrein 14. J. Biol. Chem. 2006;
  18. Brattsand M, Egelrud T. Purification, molecular cloning, and expression of a human stratum corneum trypsin-like serine protease with possible function in desquamation. J. Biol. Chem. 1999;274:30033–30040
  19. Brattsand M, Stefansson K, Lundh C, Haasum Y, Egelrud T. A proteolytic cascade of kallikreins in the stratum corneum. J. Invest. Dermatol. 2005;124:198–203
  20. Campbell DJ. The kallikrein-kinin system in humans. Clin. Exp. Pharmacol. Physiol. 2001;28:1060–1065
  21. Caubet C, Jonca N, Brattsand M, Guerrin M, Bernard D, Schmidt R, et al. Degradation of corneodesmosome proteins by two serine proteases of the kallikrein family, SCTE/KLK5/hK5 and SCCE/KLK7/hK7. J. Invest. Dermatol. 2004;122:1235–1244
  22. Chao J, Chao L. Kallikrein-kinin in stroke, cardiovascular and renal disease. Exp. Physiol. 2005;90:291–298
  23. Chao J, Bledsoe G, Yin H, Chao L. The tissue kallikrein-kinin system protects against cardiovascular and renal diseases and ischemic stroke independently of blood pressure reduction. Biol. Chem. 2006;387:665–675
  24. Chavanas S, Bodemer C, Rochat A, Hamel-Teillac D, Ali M, Irvine AD, et al. Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat. Genet. 2000;25:141–142
  25. Chen VC, Chao L, Chao J. Reactive-site specificity of human kallistatin toward tissue kallikrein probed by site-directed mutagenesis. Biochim. Biophys. Acta. 2000;1479:237–246
  26. Chen VC, Chao L, Chao J. Roles of the P1, P2, and P3 residues in determining inhibitory specificity of kallistatin toward human tissue kallikrein. J. Biol. Chem. 2000;275:38457–38466
  27. Chowdhury I, Tharakan B, Bhat GK. Current concepts in apoptosis: the physiological suicide program revisited. Cell Mol. Biol. Lett. 2006;11:506–525
  28. Christofori G. New signals from the invasive front. Nature. 2006;441:444–450
  29. Cinar B, Yeung F, Konaka H, Mayo MW, Freeman MR, Zhau HE, et al. Identification of a negative regulatory cis-element in the enhancer core region of the prostate-specific antigen promoter: implications for intersection of androgen receptor and nuclear factor-kappaB signalling in prostate cancer cells. Biochem. J. 2004;379:421–431
  30. Cleutjens KB, van Eekelen CC, van der Korput HA, Brinkmann AO, Trapman J. Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. J. Biol. Chem. 1996;271:6379–6388
  31. Cleutjens KB, van der Korput HA, van Eekelen CC, van Rooij HC, Faber PW, Trapman J. An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter. Mol. Endocrinol. 1997;11:148–161
  32. Cloutier SM, Chagas JR, Mach JP, Gygi CM, Leisinger HJ, Deperthes D. Substrate specificity of human kallikrein 2 (hK2) as determined by phage display technology. Eur. J. Biochem. 2002;269:2747–2754
  33. Colman RW. Regulation of angiogenesis by the kallikrein-kinin system. Curr. Pharm. Des. 2006;12:2599–2607
  34. Davidson B, Xi Z, Saatcioglu F. Kallikrein 4 is expressed in malignant mesothelioma—further evidence for the histogenetic link between mesothelial and epithelial cells. Diagn. Cytopathol. 2007;35:80–84
  35. Debela M, Magdolen V, Grimminger V, Sommerhoff C, Messerschmidt A, Huber R, et al. Crystal structures of human tissue kallikrein 4: activity modulation by a specific zinc binding site. J. Mol. Biol. 2006;362:1094–1107
  36. Debela M, Magdolen V, Schechter N, Valachova M, Lottspeich F, Craik CS, et al. Specificity profiling of seven human tissue kallikreins reveals individual subsite preferences. J. Biol. Chem. 2006;281:25678–25688
  37. Denmeade SR, Lovgren J, Khan SR, Lilja H, Isaacs JT. Activation of latent protease function of pro-hK2, but not pro-PSA, involves autoprocessing. Prostate. 2001;48:122–126
  38. Denmeade SR, Litvinov I, Sokoll LJ, Lilja H, Isaacs JT. Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo. Prostate. 2003;56:45–53
  39. Deperthes D. Phage display substrate: a blind method for determining protease specificity. Biol. Chem. 2002;383:1107–1112
  40. Dery O, Corvera CU, Steinhoff M, Bunnett NW. Proteinase-activated receptors: novel mechanisms of signaling by serine proteases. Am. J. Physiol. 1998;274:C1429–C1452
  41. Descargues P, Deraison C, Bonnart C, Kreft M, Kishibe M, Ishida-Yamamoto A, et al. Spink5-deficient mice mimic Netherton syndrome through degradation of desmoglein 1 by epidermal protease hyperactivity. Nat. Genet. 2005;37:56–65
  42. Descargues P, Deraison C, Prost C, Fraitag S, Mazereeuw-Hautier J, D'Alessio M, et al. Corneodesmosomal cadherins are preferential targets of stratum corneum trypsin- and chymotrypsin-like hyperactivity in Netherton syndrome. J. Invest. Dermatol. 2006;126:1622–1632
  43. Desrivieres S, Lu H, Peyri N, Soria C, Legrand Y, Menashi S. Activation of the 92kDa type IV collagenase by tissue kallikrein. J. Cell Physiol. 1993;157:587–593
  44. Diamandis EP, Scorilas A, Fracchioli S, Van Gramberen M, De Bruijn H, Henrik A, et al. Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J. Clin. Oncol. 2003;21:1035–1043
  45. Diamandis EP, Scorilas A, Kishi T, Blennow K, Luo LY, Soosaipillai A, et al. Altered kallikrein 7 and 10 concentrations in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia. Clin. Biochem. 2004;37:230–237
  46. Egelrud T, Brattsand M, Kreutzmann P, Walden M, Vitzithum K, Marx UC, et al. hK5 and hK7, two serine proteinases abundant in human skin, are inhibited by LEKTI domain 6. Br. J. Dermatol. 2005;153:1200–1203
  47. Ekholm E, Egelrud T. Stratum corneum chymotryptic enzyme in psoriasis. Arch. Dermatol. Res. 1999;291:195–200
  48. Elliott MB, Irwin DM, Diamandis EP. In silico identification and Bayesian phylogenetic analysis of multiple new mammalian kallikrein gene families. Genomics. 2006;88:591–599
  49. Emami N, Diamandis EP. Human tissue kallikreins: a road under construction. Clin. Chim. Acta. 2007;381:78–84
  50. Emanueli C, Minasi A, Zacheo A, Chao J, Chao L, Salis MB, et al. Local delivery of human tissue kallikrein gene accelerates spontaneous angiogenesis in mouse model of hindlimb ischemia. Circulation. 2001;103:125–132
  51. Espana F, Fink E, Sanchez-Cuenca J, Gilabert J, Estelles A, Witzgall K. Complexes of tissue kallikrein with protein C inhibitor in human semen and urine. Eur. J. Biochem. 1995;234:641–649
  52. Felber LM, Kundig C, Borgono CA, Chagas JR, Tasinato A, Jichlinski P, et al. Mutant recombinant serpins as highly specific inhibitors of human kallikrein 14. FEBS J. 2006;273:2505–2514
  53. Fernando SC, Najar FZ, Guo X, Zhou L, Fu Y, Geisert RD, et al. Porcine kallikrein gene family: genomic structure, mapping, and differential expression analysis. Genomics. 2007;89(3):429–438
  54. Fidler IJ. Angiogenesis and cancer metastasis. Cancer J. 2000;6(Suppl. 2):S134–S141
  55. Fortier AH, Nelson BJ, Grella DK, Holaday JW. Antiangiogenic activity of prostate-specific antigen. J. Natl. Cancer Inst. 1999;91:1635–1640
  56. Fortier AH, Holaday JW, Liang H, Dey C, Grella DK, Holland-Linn J, et al. Recombinant prostate specific antigen inhibits angiogenesis in vitro and in vivo. Prostate. 2003;56:212–219
  57. Foussias G, Yousef GM, Diamandis EP. Identification and molecular characterization of a novel member of the siglec family (SIGLEC9). Genomics. 2000;67:171–178
  58. Frenette G, Tremblay RR, Lazure C, Dube JY. Prostatic kallikrein hK2, but not prostate-specific antigen (hK3), activates single-chain urokinase-type plasminogen activator. Int. J. Cancer. 1997;71:897–899
  59. Giusti B, Serrati S, Margheri F, Papucci L, Rossi L, Poggi F, et al. The antiangiogenic tissue kallikrein pattern of endothelial cells in systemic sclerosis. Arthritis Rheum. 2005;52:3618–3628
  60. Gomis-Ruth FX, Bayes A, Sotiropoulou G, Pampalakis G, Tsetsenis T, Villegas V, et al. The structure of human prokallikrein 6 reveals a novel activation mechanism for the kallikrein family. J. Biol. Chem. 2002;277:27273–27281
  61. Goya M, Ishii G, Miyamoto S, Hasebe T, Nagai K, Yonou H, et al. Prostate-specific antigen induces apoptosis of osteoclast precursors: potential role in osteoblastic bone metastases of prostate cancer. Prostate. 2006;66:1573–1584
  62. Goyal J, Smith KM, Cowan JM, Wazer DE, Lee SW, Band V. The role for NES1 serine protease as a novel tumor suppressor. Cancer Res. 1998;58:4782–4786
  63. Hachem JP, Wagberg F, Schmuth M, Crumrine D, Lissens W, Jayakumar A, et al. Serine protease activity and residual LEKTI expression determine phenotype in Netherton syndrome. J. Invest. Dermatol. 2006;126:1609–1621
  64. Hansson L, Backman A, Ny A, Edlund M, Ekholm E, Ekstrand HB, et al. Epidermal overexpression of stratum corneum chymotryptic enzyme in mice: a model for chronic itchy dermatitis. J. Invest. Dermatol. 2002;118:444–449
  65. Hansson L, Stromqvist M, Backman A, Wallbrandt P, Carlstein A, Egelrud T. Cloning, expression, and characterization of stratum corneum chymotryptic enzyme. A skin-specific human serine proteinase. J. Biol. Chem. 1994;269:19420–19426
  66. Harris JL, Backes BJ, Leonetti F, Mahrus S, Ellman JA, Craik CS. Rapid and general profiling of protease specificity by using combinatorial fluorogenic substrate libraries. Proc. Natl. Acad. Sci. USA. 2000;97:7754–7759
  67. Hart PS, Wright JT, Savage M, Kang G, Bensen JT, Gorry MC, et al. Exclusion of candidate genes in two families with autosomal dominant hypocalcified amelogenesis imperfecta. Eur. J. Oral Sci. 2003;111:326–331
  68. Hart PS, Hart TC, Michalec MD, Ryu OH, Simmons D, Hong S, et al. Mutation in kallikrein 4 causes autosomal recessive hypomaturation amelogenesis imperfecta. J. Med. Genet. 2004;41:545–549
  69. Heidtmann HH, Nettelbeck DM, Mingels A, Jager R, Welker HG, Kontermann RE. Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen. Br. J. Cancer. 1999;81:1269–1273
  70. Ishida-Yamamoto A, Deraison C, Bonnart C, Bitoun E, Robinson R, O'Brien TJ, et al. LEKTI is localized in lamellar granules, separated from KLK5 and KLK7, and is secreted in the extracellular spaces of the superficial stratum granulosum. J. Invest. Dermatol. 2005;124:360–366
  71. Ishii K, Otsuka T, Iguchi K, Usui S, Yamamoto H, Sugimura Y, et al. Evidence that the prostate-specific antigen (PSA)/Zn2+ axis may play a role in human prostate cancer cell invasion. Cancer Lett. 2004;207:79–87
  72. Kemper C, Atkinson JP. T-cell regulation: with complements from innate immunity. Nat. Rev. Immunol. 2007;7:9–18
  73. Killian CS, Corral DA, Kawinski E, Constantine RI. Mitogenic response of osteoblast cells to prostate-specific antigen suggests an activation of latent TGF-beta and a proteolytic modulation of cell adhesion receptors. Biochem. Biophys. Res. Commun. 1993;192:940–947
  74. Kim JW, Simmer JP, Lin BP, Seymen F, Bartlett JD, Hu JC. Mutational analysis of candidate genes in 24 amelogenesis imperfecta families. Eur. J. Oral Sci. 2006;114(Suppl. 1):3–12
  75. Kishi T, Grass L, Soosaipillai A, Scorilas A, Harbeck N, Schmalfeldt B, et al. Human kallikrein 8, a novel biomarker for ovarian carcinoma. Cancer Res. 2003;63:2771–2774
  76. Kishi T, Cloutier SM, Kundig C, Deperthes D, Diamandis EP. Activation and enzymatic characterization of recombinant human kallikrein 8. Biol. Chem. 2006;387:723–731
  77. Kishibe M, Bando Y, Terayama R, Namikawa K, Takahashi H, Hashimoto Y, et al. Kallikrein 8 is involved in skin desquamation in cooperation with other kallikreins. J. Biol. Chem. 2006;282:5834–5841
  78. Koistinen H, Paju A, Koistinen R, Finne P, Lovgren J, Wu P, et al. Prostate-specific antigen and other prostate-derived proteases cleave IGFBP-3, but prostate cancer is not associated with proteolytically cleaved circulating IGFBP-3. Prostate. 2002;50:112–118
  79. Komatsu N, Takata M, Otsuki N, Ohka R, Amano O, Takehara K, et al. Elevated stratum corneum hydrolytic activity in Netherton syndrome suggests an inhibitory regulation of desquamation by SPINK5-derived peptides. J. Invest. Dermatol. 2002;118:436–443
  80. Komatsu N, Saijoh K, Sidiropoulos M, Tsai B, Levesque MA, Elliott MB, et al. Quantification of human tissue kallikreins in the stratum corneum: dependence on age and gender. J. Invest. Dermatol. 2005;125:1182–1189
  81. Komatsu N, Saijoh K, Toyama T, Ohka R, Otsuki N, Hussack G, et al. Multiple tissue kallikrein mRNA and protein expression in normal skin and skin diseases. Br. J. Dermatol. 2005;153:274–281
  82. Komatsu N, Suga Y, Saijoh K, Liu AC, Khan S, Mizuno Y, et al. Elevated human tissue kallikrein levels in the stratum corneum and serum of peeling skin syndrome-type B patients suggests an over-desquamation of corneocytes. J. Invest. Dermatol. 2006;126:2338–2342
  83. Komatsu N, Saijoh K, Otsuki N, Kishi T, Micheal IP, Obiezu CV, et al. Proteolytic processing of human growth hormone by multiple tissue kallikreins and regulation by the serine protease inhibitor Kazal-Type5 (SPINK5) protein. Clin. Chim. Acta. 2007;377:228–236
  84. Kumar A, Goel AS, Hill TM, Mikolajczyk SD, Millar LS, Kuus-Reichel K, et al. Expression of human glandular kallikrein, hK2, in mammalian cells. Cancer Res. 1996;56:5397–5402
  85. Kumar A, Mikolajczyk SD, Goel AS, Millar LS, Saedi MS. Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res. 1997;57:3111–3114
  86. Kurlender L, Yousef GM, Memari N, Robb JD, Michael IP, Borgono C, et al. Differential expression of a human kallikrein 5 (KLK5) splice variant in ovarian and prostate cancer. Tumour. Biol. 2004;25:149–156
  87. Kyriakopoulou LG, Yousef GM, Scorilas A, Katsaros D, Massobrio M, Fracchioli S, et al. Prognostic value of quantitatively assessed KLK7 expression in ovarian cancer. Clin. Biochem. 2003;36:135–143
  88. Lai J, Kedda MA, Hinze K, Smith RL, Yaxley J, Spurdle AB, et al. PSA/KLK3 AREI promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibility. Carcinogenesis. 2006;28:1032–1039
  89. Lauber T, Schulz A, Schweimer K, Adermann K, Marx UC. Homologous proteins with different folds: the three-dimensional structures of domains 1 and 6 of the multiple Kazal-type inhibitor LEKTI. J. Mol. Biol. 2003;328:205–219
  90. Laxmikanthan G, Blaber SI, Bernett MJ, Scarisbrick IA, Juliano MA, Blaber M. 1.70 A X-ray structure of human apo kallikrein 1: structural changes upon peptide inhibitor/substrate binding. Proteins. 2005;58:802–814
  91. Li B, Goyal J, Dhar S, Dimri G, Evron E, Sukumar S, et al. CpG methylation as a basis for breast tumor-specific loss of NES1/kallikrein 10 expression. Cancer Res. 2001;61:8014–8021
  92. Lovgren J, Rajakoski K, Karp M, Lundwall A, Lilja H. Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. Biochem. Biophys. Res. Commun. 1997;238:549–555
  93. Lovgren J, Airas K, Lilja H. Enzymatic action of human glandular kallikrein 2 (hK2). Substrate specificity and regulation by Zn2+ and extracellular protease inhibitors. Eur. J. Biochem. 1999;262:781–789
  94. Lovgren J, Valtonen-Andre C, Marsal K, Lilja H, Lundwall A. Measurement of prostate-specific antigen and human glandular kallikrein 2 in different body fluids. J. Androl. 1999;20:348–355
  95. Lundwall A, Band V, Blaber M, Clements JA, Courty Y, Diamandis EP, et al. A comprehensive nomenclature for serine proteases with homology to tissue kallikreins. Biol. Chem. 2006;387:637–641
  96. Lundwall A, Clauss A, Olsson AY. Evolution of kallikrein-related peptidases in mammals and identification of a genetic locus encoding potential regulatory inhibitors. Biol. Chem. 2006;387:243–249
  97. Luo LY, Jiang W. Inhibition profiles of human tissue kallikreins by serine protease inhibitors. Biol. Chem. 2006;387:813–816
  98. Luo LY, Katsaros D, Scorilas A, Fracchioli S, Bellino R, Van Gramberen M, et al. The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Cancer Res. 2003;63:807–811
  99. Luo LY, Shan SJ, Elliott MB, Soosaipillai A, Diamandis EP. Purification and characterization of human kallikrein 11, a candidate prostate and ovarian cancer biomarker, from seminal plasma. Clin. Cancer Res. 2006;12:742–750
  100. Magert HJ, Kreutzmann P, Standker L, Walden M, Drogemuller K, Forssmann WG. LEKTI: a multidomain serine proteinase inhibitor with pathophysiological relevance. Int. J. Biochem. Cell Biol. 2002;34:573–576
  101. Magklara A, Brown TJ, Diamandis EP. Characterization of androgen receptor and nuclear receptor co-regulator expression in human breast cancer cell lines exhibiting differential regulation of kallikreins 2 and 3. Int. J. Cancer. 2002;100:507–514
  102. Magklara A, Mellati AA, Wasney GA, Little SP, Sotiropoulou G, Becker GW, et al. Characterization of the enzymatic activity of human kallikrein 6: autoactivation, substrate specificity, and regulation by inhibitors. Biochem. Biophys. Res. Commun. 2003;307:948–955
  103. Malm J, Hellman J, Hogg P, Lilja H. Enzymatic action of prostate-specific antigen (PSA or hK3): substrate specificity and regulation by Zn(2+), a tight-binding inhibitor. Prostate. 2000;45:132–139
  104. Matsumura M, Bhatt AS, Andress D, Clegg N, Takayama TK, Craik CS, et al. Substrates of the prostate-specific serine protease prostase/KLK4 defined by positional-scanning peptide libraries. Prostate. 2005;62:1–13
  105. Memari N, Jiang W, Diamandis EP, Luo LY. Enzymatic properties of human kallikrein-related peptidase 12 (KLK12). Biol. Chem. 2007;388:427–435
  106. Menashi S, Fridman R, Desrivieres S, Lu H, Legrand Y, Soria C. Regulation of 92-kDa gelatinase B activity in the extracellular matrix by tissue kallikrein. Ann. N.Y. Acad. Sci. 1994;732:466–468
  107. Michael IP, Sotiropoulou G, Pampalakis G, Magklara A, Ghosh M, Wasney G, et al. Biochemical and enzymatic characterization of human kallikrein 5 (hK5), a novel serine protease potentially involved in cancer progression. J. Biol. Chem. 2005;280:14628–14635
  108. Michael IP, Pampalakis G, Mikolajczyk SD, Malm J, Sotiropoulou G, Diamandis EP. Human tissue kallikrein 5 is a member of a proteolytic cascade pathway involved in seminal clot liquefaction and potentially in prostate cancer progression. J. Biol. Chem. 2006;281:12743–12750
  109. Mikolajczyk SD, Millar LS, Kumar A, Saedi MS. Prostatic human kallikrein 2 inactivates and complexes with plasminogen activator inhibitor-1. Int. J. Cancer. 1999;81:438–442
  110. Moreau ME, Garbacki N, Molinaro G, Brown NJ, Marceau F, Adam A. The kallikrein-kinin system: current and future pharmacological targets. J. Pharmacol. Sci. 2005;99:6–38
  111. Murtha P, Tindall DJ, Young CY. Androgen induction of a human prostate-specific kallikrein, hKLK2: characterization of an androgen response element in the 5′ promoter region of the gene. Biochemistry. 1993;32:6459–6464
  112. Obiezu CV, Diamandis EP. Human tissue kallikrein gene family: applications in cancer. Cancer Lett. 2005;224:1–22
  113. Obiezu CV, Michael IP, Levesque MA, Diamandis EP. Human kallikrein 4: enzymatic activity, inhibition, and degradation of extracellular matrix proteins. Biol. Chem. 2006;387:749–759
  114. Oikonomopoulou K, Hansen KK, Saifeddine M, Tea I, Blaber M, Blaber SI, et al. Proteinase-activated receptors, targets for kallikrein signaling. J. Biol. Chem. 2006;281:32095–32112
  115. Paliouras M, Diamandis EP. Coordinated steroid hormone-dependent and independent expression of multiple kallikreins in breast cancer cell lines. Breast Cancer Res. Treat. 2006;102:7–19
  116. Paliouras M, Diamandis EP. The kallikrein world: an update on the human tissue kallikreins. Biol. Chem. 2006;387:643–652
  117. Paliouras M, Borgono C, Diamandis EP. Human tissue kallikreins: the cancer biomarker family. Cancer Lett. 2007;249:61–79
  118. Pampalakis G, Sotiropoulou G. Multiple mechanisms underlie the aberrant expression of the human kallikrein 6 gene in breast cancer. Biol. Chem. 2006;387:773–782
  119. Peternac D, Klima I, Cecchini MG, Studer UE, Thalmann GN. Prostate specific antigen expression does not necessarily correlate with prostate cancer cell growth. J. Urol. 2006;176:354–360
  120. Petraki CD, Karavana VN, Skoufogiannis PT, Little SP, Howarth DJ, Yousef GM, et al. The spectrum of human kallikrein 6 (zyme/protease M/neurosin) expression in human tissues as assessed by immunohistochemistry. J. Histochem. Cytochem. 2001;49:1431–1441
  121. Petraki CD, Karavana VN, Luo LY, Diamandis EP. Human kallikrein 10 expression in normal tissues by immunohistochemistry. J. Histochem. Cytochem. 2002;50:1247–1261
  122. Petraki CD, Karavana VN, Diamandis EP. Human kallikrein 13 expression in normal tissues: an immunohistochemical study. J. Histochem. Cytochem. 2003;51:493–501
  123. Picard D. Chaperoning steroid hormone action. Trends Endocrinol. Metab. 2006;17:229–235
  124. Pinkus GS, Maier M, Seldin DC, ole-MoiYoi OK, Austen KF, Spragg J. Immunohistochemical localization of glandular kallikrein in the endocrine and exocrine human pancreas. J. Histochem. Cytochem. 1983;31:1279–1288
  125. Prezas P, Scorilas A, Yfanti C, Viktorov P, Agnanti N, Diamandis E, et al. The role of human tissue kallikreins 7 and 8 in intracranial malignancies. Biol. Chem. 2006;387:1607–1612
  126. Rajapakse S, Ogiwara K, Takano N, Moriyama A, Takahashi T. Biochemical characterization of human kallikrein 8 and its possible involvement in the degradation of extracellular matrix proteins. FEBS Lett. 2005;579:6879–6884
  127. Rawlings ND, Barrett AJ. Families of serine peptidases. Methods Enzymol. 1994;244:19–61
  128. Rehault S, Monget P, Mazerbourg S, Tremblay R, Gutman N, Gauthier F, et al. Insulin-like growth factor binding proteins (IGFBPs) as potential physiological substrates for human kallikreins hK2 and hK3. Eur. J. Biochem. 2001;268:2960–2968
  129. Rittenhouse HG, Finlay JA, Mikolajczyk SD, Partin AW. Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. Crit. Rev. Clin. Lab Sci. 1998;35:275–368
  130. Rochette-Egly C. Nuclear receptors: integration of multiple signalling pathways through phosphorylation. Cell Signal. 2003;15:355–366
  131. Romanov VI, Whyard T, Adler HL, Waltzer WC, Zucker S. Prostate cancer cell adhesion to bone marrow endothelium: the role of prostate-specific antigen. Cancer Res. 2004;64:2083–2089
  132. Rosenfeld RG. Insulin-like growth factors and the basis of growth. N. Engl. J. Med. 2003;349:2184–2186
  133. Rousseau GG. Control of gene expression by glucocorticoid hormones. Biochem. J. 1984;224:1–12
  134. Samani AA, Yakar S, Leroith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr. Rev. 2006;28:20–47
  135. Saunders WB, Bayless KJ, Davis GE. MMP-1 activation by serine proteases and MMP-10 induces human capillary tubular network collapse and regression in 3D collagen matrices. J. Cell Sci. 2005;118:2325–2340
  136. Schechter NM, Choi EJ, Wang ZM, Hanakawa Y, Stanley JR, Kang Y, et al. Inhibition of human kallikreins 5 and 7 by the serine protease inhibitor lympho-epithelial Kazal-type inhibitor (LEKTI). Biol. Chem. 2005;386:1173–1184
  137. Schenone M, Furie BC, Furie B. The blood coagulation cascade. Curr. Opin. Hematol. 2004;11:272–277
  138. Schuur ER, Henderson GA, Kmetec LA, Miller JD, Lamparski HG, Henderson DR. Prostate-specific antigen expression is regulated by an upstream enhancer. J. Biol. Chem. 1996;271:7043–7051
  139. Scorilas A, Borgono CA, Harbeck N, Dorn J, Schmalfeldt B, Schmitt M, et al. Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker. J. Clin. Oncol. 2004;22:678–685
  140. Sharma JN. Role of tissue kallikrein-kininogen-kinin pathways in the cardiovascular system. Arch. Med. Res. 2006;37:299–306
  141. Shimizu C, Yoshida S, Shibata M, Kato K, Momota Y, Matsumoto K, et al. Characterization of recombinant and brain neuropsin, a plasticity-related serine protease. J. Biol. Chem. 1998;273:11189–11196
  142. Sidenius N, Blasi F. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev. 2003;22:205–222
  143. Sidera C, Parsons R, Austen B. Proteolytic cascade in the amyloidogenesis of Alzheimer's disease. Biochem. Soc. Trans. 2004;32:33–36
  144. Sidiropoulos M, Pampalakis G, Sotiropoulou G, Katsaros D, Diamandis EP. Downregulation of human kallikrein 10 (KLK10/NES1) by CpG island hypermethylation in breast, ovarian and prostate cancers. Tumour. Biol. 2005;26:324–336
  145. Silverman GA, Bird PI, Carrell RW, Church FC, Coughlin PB, Gettins PG, et al. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J. Biol. Chem. 2001;276:33293–33296
  146. Simmer JP, Fukae M, Tanabe T, Yamakoshi Y, Uchida T, Xue J, et al. Purification, characterization, and cloning of enamel matrix serine proteinase 1. J. Dent. Res. 1998;77:377–386
  147. Sohara Y, Shimada H, DeClerck YA. Mechanisms of bone invasion and metastasis in human neuroblastoma. Cancer Lett. 2005;228:203–209
  148. Sondell B, Thornell LE, Egelrud T. Evidence that stratum corneum chymotryptic enzyme is transported to the stratum corneum extracellular space via lamellar bodies. J. Invest. Dermatol. 1995;104:819–823
  149. Sotiropoulou G, Rogakos V, Tsetsenis T, Pampalakis G, Zafiropoulos N, Simillides G, et al. Emerging interest in the kallikrein gene family for understanding and diagnosing cancer. Oncol. Res. 2003;13:381–391
  150. Sprecher E, Chavanas S, DiGiovanna JJ, Amin S, Nielsen K, Prendiville JS, et al. The spectrum of pathogenic mutations in SPINK5 in 19 families with Netherton syndrome: implications for mutation detection and first case of prenatal diagnosis. J. Invest. Dermatol. 2001;117:179–187
  151. Stefansson K, Brattsand M, Ny A, Glas B, Egelrud T. Kallikrein-related peptidase 14 may be a major contributor to trypsin-like proteolytic activity in human stratum corneum. Biol. Chem. 2006;387:761–768
  152. Stege R, Grande M, Carlstrom K, Tribukait B, Pousette A. Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas. Clin. Cancer Res. 2000;6:160–165
  153. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res. 1991;51:222–226
  154. Stephan C, Yousef GM, Scorilas A, Jung K, Jung M, Kristiansen G, et al. Quantitative analysis of kallikrein 15 gene expression in prostate tissue. J. Urol. 2003;169:361–364
  155. Stephanopoulos G, Garefalaki ME, Lyroudia K. Genes and related proteins involved in amelogenesis imperfecta. J. Dent. Res. 2005;84:1117–1126
  156. Sun Z, Pan J, Balk SP. Androgen receptor-associated protein complex binds upstream of the androgen-responsive elements in the promoters of human prostate-specific antigen and kallikrein 2 genes. Nucleic Acids Res. 1997;25:3318–3325
  157. Takayama TK, McMullen BA, Nelson PS, Matsumura M, Fujikawa K. Characterization of hK4 (prostase), a prostate-specific serine protease: activation of the precursor of prostate specific antigen (pro-PSA) and single-chain urokinase-type plasminogen activator and degradation of prostatic acid phosphatase. Biochemistry. 2001;40:15341–15348
  158. Talieri M, Diamandis EP, Gourgiotis D, Mathioudaki K, Scorilas A. Expression analysis of the human kallikrein 7 (KLK7) in breast tumors: a new potential biomarker for prognosis of breast carcinoma. Thromb. Haemost. 2004;91:180–186
  159. Tamura H, Ishikawa Y, Hino N, Maeda M, Yoshida S, Kaku S, et al. Neuropsin is essential for early processes of memory acquisition and Schaffer collateral long-term potentiation in adult mouse hippocampus in vivo. J. Physiol. 2006;570:541–551
  160. Tarttelin EE, Bellingham J, Hankins MW, Foster RG, Lucas RJ. Neuropsin (Opn5): a novel opsin identified in mammalian neural tissue. FEBS Lett. 2003;554:410–416
  161. Terayama R, Bando Y, Takahashi T, Yoshida S. Differential expression of neuropsin and protease M/neurosin in oligodendrocytes after injury to the spinal cord. Glia. 2004;48:91–101
  162. Thornberry NA, Rano TA, Peterson EP, Rasper DM, Timkey T, Garcia-Calvo M, et al. A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis. J. Biol. Chem. 1997;272:17907–17911
  163. Vaisanen V, Lovgren J, Hellman J, Piironen T, Lilja H, Pettersson K. Characterization and processing of prostate specific antigen (hK3) and human glandular kallikrein (hK2) secreted by LNCaP cells. Prostate Cancer Prostatic. Dis. 1999;2:91–97
  164. Veveris-Lowe TL, Lawrence MG, Collard RL, Bui L, Herington AC, Nicol DL, et al. Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells. Endocr. Relat Cancer. 2005;12:631–643
  165. Wang Y. The role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer invasion and metastasis. Med. Res. Rev. 2001;21:146–170
  166. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest. Urol. 1979;17:159–163
  167. Wang C, Yeung F, Liu PC, Attar RM, Geng J, Chung LW, et al. Identification of a novel transcription factor, GAGATA-binding protein, involved in androgen-mediated expression of prostate-specific antigen. J. Biol. Chem. 2003;278:32423–32430
  168. Webber MM, Waghray A, Bello D. Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. Clin. Cancer Res. 1995;1:1089–1094
  169. Wright JT, Daly B, Simmons D, Hong S, Hart SP, Hart TC, et al. Human enamel phenotype associated with amelogenesis imperfecta and a kallikrein-4 (g.2142G>A) proteinase mutation. Eur. J. Oral Sci. 2006;114(Suppl. 1):13–17
  170. Yakar S, Liu JL, Stannard B, Butler A, Accili D, Sauer B, et al. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc. Natl. Acad. Sci. USA. 1999;96:7324–7329
  171. Yamakoshi Y, Hu JC, Fukae M, Yamakoshi F, Simmer JP. How do enamelysin and kallikrein 4 process the 32-kDa enamelin?. Eur. J. Oral Sci. 2006;114(Suppl. 1):45–51
  172. Yamasaki K, Schauber J, Coda A, Lin H, Dorschner RA, Schechter NM, et al. Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin. FASEB J. 2006;20:2068–2080
  173. Yao YY, Yin H, Shen B, Chao L, Chao J. Tissue kallikrein infusion prevents cardiomyocyte apoptosis, inflammation and ventricular remodeling after myocardial infarction. Regul. Pept. 2006;140:12–20
  174. Yonou H, Aoyagi Y, Kanomata N, Kamijo T, Oda T, Yokose T, et al. Prostate-specific antigen induces osteoplastic changes by an autonomous mechanism. Biochem. Biophys. Res. Commun. 2001;289:1082–1087
  175. Yousef GM, Diamandis EP. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr. Rev. 2001;22:184–204
  176. Yousef GM, Diamandis EP. Human tissue kallikreins: a new enzymatic cascade pathway?. Biol. Chem. 2002;383:1045–1057
  177. Yousef GM, Diamandis M, Jung K, Diamandis EP. Molecular cloning of a novel human acid phosphatase gene (ACPT) that is highly expressed in the testis. Genomics. 2001;74:385–395
  178. Yousef GM, Kyriakopoulou LG, Scorilas A, Fracchioli S, Ghiringhello B, Zarghooni M, et al. Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker. Cancer Res. 2001;61:7811–7818
  179. Yousef GM, Kishi T, Diamandis EP. Role of kallikrein enzymes in the central nervous system. Clin. Chim. Acta. 2003;329:1–8
  180. Yousef GM, Polymeris ME, Grass L, Soosaipillai A, Chan PC, Scorilas A, et al. Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer. Cancer Res. 2003;63:3958–3965
  181. Yousef GM, Scorilas A, Nakamura T, Ellatif MA, Ponzone R, Biglia N, et al. The prognostic value of the human kallikrein gene 9 (KLK9) in breast cancer. Breast Cancer Res. Treat. 2003;78:149–158
  182. Yousef GM, White NM, Michael IP, Cho JC, Robb JD, Kurlender L, et al. Identification of new splice variants and differential expression of the human kallikrein 10 gene, a candidate cancer biomarker. Tumour. Biol. 2005;26:227–235
  183. Yu H, Levesque MA, Clark GM, Diamandis EP. Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study. Clin. Cancer Res. 1998;4:1489–1497
  184. Yu DC, Sakamoto GT, Henderson DR. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy. Cancer Res. 1999;59:1498–1504
  185. Zhao R, Houry WA. Hsp90: a chaperone for protein folding and gene regulation. Biochem. Cell Biol. 2005;83:703–710

PII: S1574-7891(07)00071-3

doi: 10.1016/j.molonc.2007.09.003

Molecular Oncology
Volume 1, Issue 3 , Pages 269-287 , December 2007

Article Tools

* Image Usage & Resolution